Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
Analyst believes impressive Phase 3 data read-out bolsters expectations for lefamulin’s peak sales potential.
Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.
Solid MNK business model will eventually attract investors, says analyst.
Amarin Ventures to Shield Omega-3 Candidate Vascepa from Adverse Competition
TEVA’s Brand Drug Portfolio and Pipeline Are Undervalued, Says Analyst
Novartis’ Results Could Be a Good Looking Glass into Successful Commercial Future for Amarin
Looking for a reason to buy shares of Opko Health Inc. (NASDAQ:OPK)?
Cantor analyst Louise Chen had the opportunity to discuss this morning with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) management regarding some concern that formulary changes …